<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03667313</url>
  </required_header>
  <id_info>
    <org_study_id>FNO-TIS 2</org_study_id>
    <nct_id>NCT03667313</nct_id>
  </id_info>
  <brief_title>Treatment of In-Stent Restenosis 2 Study</brief_title>
  <acronym>TIS2</acronym>
  <official_title>Prospective Randomised Study Comparing Efficacy of Treatment Coronary In-stent Restenosis Using Sirolimus-Eluting and Iopromide-Coated Paclitaxel-Eluting Balloon Catheters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Ostrava</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the efficacy of sirolimus-eluting balloon catheters (SEB)
      and iopromide-coated paclutaxel-eluting balloon catheters (PEB) in the treatment of bare
      metal (BMS) - or drug-eluting stents restenosis (DES-ISR).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current therapy for in-stent restenosis (ISR) is based on the drug-eluting stents (DES) or
      drug-eluting balloon catheters (DEB). In clinical practice, paclitaxel is used as an
      effective antiproliferative agent loaded into DEB (paclitaxel-eluting balloon catheters;
      PEB).

      In contrast to paclitaxel, sirolimus is difficult to deliver on the balloon surface, due to
      insufficient tissue uptake and shorter tissue retention of limus drugs. It was found that
      phospholipid-encapsulated sirolimus nanoparticles could be used for coating balloon catheters
      to provide efficient drug transfer to vessel wall with high tissue concentration.

      This prospective randomized non-inferiority study compares the efficacy of new
      sirolimus-eluting balloon catheters (SEB) and iopromide-coated paclutaxel-eluting balloon
      catheters (PEB) in the treatment of bare metal (BMS) - or drug-eluting stents restenosis
      (DES-ISR).

      The primary end-point is in-segment late lumen loss (LLL) at 12 months as measured by
      quantitative coronary angiography (QCA).

      Secondary end-points are the incidence of binary ISR (˃50% DS) and the overall incidence of
      12-month major adverse cardiac events (MACE; cardiovascular death, non-fatal acute myocardial
      infarction [AIM], or target vessel revascularization [TVR]).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late lumem loss (LLL)</measure>
    <time_frame>12-month</time_frame>
    <description>the diference between post-intervention mimimal lumen diameter (MLD) and 12-month MLD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>repeated binary restenosis</measure>
    <time_frame>12-month</time_frame>
    <description>recurrence of stenosis ≥50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major adverse cardiac events (MACE)</measure>
    <time_frame>12-month</time_frame>
    <description>cardiovascular death, non-fatal acute myocardial infarction [AIM], or target vessel revascularization [TVR]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>sirolimus-eluting balloon (SEB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment of bare-metal (BMS) or drug-eluting in-stent restenosis (DES-ISR) with SEB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>paclitaxel-eluting balloon (PEB)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment of BMS- or DES-ISR with PEB</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sirolimus-eluting balloon (SEB) MagicTouch</intervention_name>
    <description>Patients with coronary in-stent restenosis treated with sirolimus-eluting balloon</description>
    <arm_group_label>sirolimus-eluting balloon (SEB)</arm_group_label>
    <other_name>MagicTouch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>paclitaxel-eluting balloon (PEB) Sequent Please</intervention_name>
    <description>Patients with coronary in-stent restenosis treated with paclitaxel-eluting balloon</description>
    <arm_group_label>paclitaxel-eluting balloon (PEB)</arm_group_label>
    <other_name>Sequent Please</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with BMS- or DES-ISR (˃50% diameter stenosis; DS)

          -  ≥18 years of age

          -  willing to sign an Informed consent

        Exclusion Criteria:

          -  concomitant diseases with an expected survival time of less than 12 months

          -  or that limited the possibility of control coronary aniography (e.g., advanced renal
             failure).

          -  impossibility of long-term (6 months) dual antiplatelet treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leos Pleva, MD,PhD</last_name>
    <phone>733414740</phone>
    <email>leos.pleva@volny.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiovascular Department of University Hospital</name>
      <address>
        <city>Ostrava</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leos Pleva, MD, PhD</last_name>
      <phone>733414740</phone>
      <email>leos.pleva@volny.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>November 23, 2018</last_update_submitted>
  <last_update_submitted_qc>November 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>in-stent restenosis; sirolimus-; paclitaxel-eluting balloon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

